Immunology and Respiratory Research

Boehringer Ingelheim is one of the leading pharmaceutical companies worldwide in the treatment of respiratory diseases.

It has been recognized that respiratory diseases such as COPD or Asthma are heterozygous syndromes that are often associated with an aberrant immune response of the afflicted patient. Therefore it made sense to create a new Discovery Research Therapeutic Area that combines our long-standing competence and success story in respiratory diseases with our expertise in immunology.

Within this newly formed department, more than 200 scientists work in our fully integrated drug discovery centre of excellence for Immunology and Respiratory Diseases research at sites in Biberach, Germany and Ridgefield, CT, USA.

Our Discovery Research focus is on:

  • Crohn’s disease & ulcerative colitis

  • Systemic lupus erythematosus/lupus nephritis

  • Rheumatoid arthritis

  • Systemic sclerosis-scleroderma

  • Chronic obstructive pulmonary disease (COPD)

  • Asthma

  • Pulmonary fibrosis

  • Cystic fibrosis

  • Acute respiratory distress syndrome (ARDS)

 

  • Strategi

    Fokusområder

    Vores strategi inden for ny forskning sigter på at styrke vores evne til at skabe innovation og fremme den videnskabelige kreativitet indenfor sygdomsområder, hvor der er et udækket medicinsk behov.

    Læs mere on

    Fokusområder